AU2019388899A1 - Methods of treating follicular lymphoma - Google Patents
Methods of treating follicular lymphoma Download PDFInfo
- Publication number
- AU2019388899A1 AU2019388899A1 AU2019388899A AU2019388899A AU2019388899A1 AU 2019388899 A1 AU2019388899 A1 AU 2019388899A1 AU 2019388899 A AU2019388899 A AU 2019388899A AU 2019388899 A AU2019388899 A AU 2019388899A AU 2019388899 A1 AU2019388899 A1 AU 2019388899A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- ibrutinib
- mutations
- genes
- follicular lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773678P | 2018-11-30 | 2018-11-30 | |
| US62/773,678 | 2018-11-30 | ||
| PCT/US2019/063234 WO2020112761A1 (en) | 2018-11-30 | 2019-11-26 | Methods of treating follicular lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019388899A1 true AU2019388899A1 (en) | 2021-06-10 |
Family
ID=68966021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019388899A Abandoned AU2019388899A1 (en) | 2018-11-30 | 2019-11-26 | Methods of treating follicular lymphoma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200171034A1 (https=) |
| EP (1) | EP3886992A1 (https=) |
| JP (1) | JP2022513666A (https=) |
| KR (1) | KR20210097160A (https=) |
| CN (1) | CN113164782A (https=) |
| AU (1) | AU2019388899A1 (https=) |
| BR (1) | BR112021009978A2 (https=) |
| CA (1) | CA3120960A1 (https=) |
| EA (1) | EA202191509A1 (https=) |
| IL (1) | IL283365A (https=) |
| JO (1) | JOP20210126A1 (https=) |
| MA (1) | MA54292A (https=) |
| MX (1) | MX2021006368A (https=) |
| PH (1) | PH12021551140A1 (https=) |
| SG (1) | SG11202105309YA (https=) |
| WO (1) | WO2020112761A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| CA2914284A1 (en) * | 2013-05-30 | 2014-12-04 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US20160032404A1 (en) * | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
| CA2980393A1 (en) * | 2015-03-18 | 2016-09-22 | Memorial Sloan Kettering Cancer Center | Methods for diagnosing and treating follicular lymphoma |
| HK1250925A1 (zh) * | 2015-04-06 | 2019-01-18 | Janssen Pharmaceutica, N.V. | 包含依鲁替尼的组合物 |
| WO2017087947A2 (en) * | 2015-11-19 | 2017-05-26 | Pharmacyclics Llc | Method of treatment of follicular lymphoma with a btk inhibitor |
| PH12021551936A1 (en) * | 2019-02-15 | 2022-05-23 | Janssen Biotech Inc | Combination therapy for treatment of b-cell malignancies |
-
2019
- 2019-11-26 EP EP19824085.5A patent/EP3886992A1/en not_active Withdrawn
- 2019-11-26 EA EA202191509A patent/EA202191509A1/ru unknown
- 2019-11-26 MX MX2021006368A patent/MX2021006368A/es unknown
- 2019-11-26 CA CA3120960A patent/CA3120960A1/en active Pending
- 2019-11-26 SG SG11202105309YA patent/SG11202105309YA/en unknown
- 2019-11-26 KR KR1020217020004A patent/KR20210097160A/ko not_active Withdrawn
- 2019-11-26 US US16/696,092 patent/US20200171034A1/en not_active Abandoned
- 2019-11-26 JO JOP/2021/0126A patent/JOP20210126A1/ar unknown
- 2019-11-26 AU AU2019388899A patent/AU2019388899A1/en not_active Abandoned
- 2019-11-26 BR BR112021009978-6A patent/BR112021009978A2/pt not_active IP Right Cessation
- 2019-11-26 WO PCT/US2019/063234 patent/WO2020112761A1/en not_active Ceased
- 2019-11-26 JP JP2021530872A patent/JP2022513666A/ja not_active Ceased
- 2019-11-26 CN CN201980078851.9A patent/CN113164782A/zh active Pending
- 2019-11-26 MA MA054292A patent/MA54292A/fr unknown
-
2021
- 2021-05-19 PH PH12021551140A patent/PH12021551140A1/en unknown
- 2021-05-23 IL IL283365A patent/IL283365A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113164782A (zh) | 2021-07-23 |
| JOP20210126A1 (ar) | 2019-11-26 |
| SG11202105309YA (en) | 2021-06-29 |
| KR20210097160A (ko) | 2021-08-06 |
| EP3886992A1 (en) | 2021-10-06 |
| US20200171034A1 (en) | 2020-06-04 |
| JP2022513666A (ja) | 2022-02-09 |
| EA202191509A1 (ru) | 2021-10-26 |
| BR112021009978A2 (pt) | 2021-08-17 |
| WO2020112761A1 (en) | 2020-06-04 |
| MA54292A (fr) | 2021-10-06 |
| PH12021551140A1 (en) | 2021-10-25 |
| IL283365A (en) | 2021-07-29 |
| MX2021006368A (es) | 2021-10-13 |
| CA3120960A1 (en) | 2020-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spina et al. | Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma | |
| Kim et al. | CD79B and MYD88 mutations in diffuse large B-cell lymphoma | |
| Armand et al. | A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphoma | |
| CN111534585A (zh) | 一种非小细胞肺癌（nsclc）患者免疫疗法预后的方法 | |
| Pagadala et al. | Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response | |
| Schürch et al. | Tumor heterogeneity in lymphomas: a different breed | |
| KR20210049117A (ko) | 기관지 전암성 병변 중증도 및 진행과 관련된 방법 | |
| Leprieur et al. | Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression | |
| Pyo et al. | Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer | |
| EP3077001B1 (en) | Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance | |
| Takashima et al. | Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma | |
| Visconte et al. | Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts | |
| Gao et al. | High‐level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome | |
| Chen et al. | Clinical management updates in mantle cell lymphoma | |
| Ruan | Molecular profiling and management of mantle cell lymphoma | |
| Mo et al. | A six-gene prognostic model based on neutrophil extracellular traps (NETs)-related gene signature for lung adenocarcinoma | |
| Kim et al. | First-line afatinib in patients with non-small-cell lung cancer with uncommon EGFR mutations in South Korea | |
| Sivanand et al. | The neoantigen landscape of mycosis fungoides | |
| JP2010535517A (ja) | Ｅｇｆｒ阻害因子治療のための予測マーカー | |
| WO2020112761A1 (en) | Methods of treating follicular lymphoma | |
| Chao et al. | Malignant triton tumor in a patient with Li‐Fraumeni syndrome and a novel TP53 mutation | |
| Shatara et al. | ATRT-21. Rhabdoid predisposition syndrome: report of molecular profiles and treatment approach in three children with synchronous atypical teratoid/rhabdoid tumor and malignant rhabdoid tumor | |
| US20250019766A1 (en) | Tumor cell identification by mapping mutations in bulk dna sequences to single cell rna sequences | |
| Pagadala | Using Germline Variation to Study Inter-Individual Variability in Cancer Risk and Host Anti-Tumor Immune Response | |
| Duran | Upregulated Acute Systemic Inflammation-Related Genes based on Endotoxin Exposure Provide “Survival Benefit” or Create “High Risk of Death” in Leukaemia and Colon Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |